The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of the immune microenvironment and spatial phenotypes across HER2 subtypes in advanced or metastatic breast cancer.
 
Ayse Koksoy
No Relationships to Disclose
 
Burak Uzunparmak
No Relationships to Disclose
 
Gabriela Raso
No Relationships to Disclose
 
Raymond Perez
Employment - Sanofi
 
Lei Wang
Employment - Sanofi
 
Ozlem Yildirim
No Relationships to Disclose
 
Giovanni Abbadessa
Employment - Alexion Pharmaceuticals (I); Sanofi
Leadership - ModeX Therapeutics
Stock and Other Ownership Interests - Alexion Pharmaceuticals (I); OPKO Health; Sanofi
Patents, Royalties, Other Intellectual Property - patents on Alexion experimental drugs (I); patents on Sanofi experimental anti-cancer drugs
 
Serena Masciari
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Elizve Barrientos-Toro
No Relationships to Disclose
 
Harsh Batra
No Relationships to Disclose
 
Edwin Parra Cuentas
No Relationships to Disclose
 
Yasmeen Rizvi
No Relationships to Disclose
 
Rossana Lazcano Segura
No Relationships to Disclose
 
Qingqing Ding
No Relationships to Disclose
 
Stephane Champiat
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai Europe; Fresenius Kabi; Genmab; Janssen; Merck KGaA; Merck Serono; MSD; Novartis; Roche; SERVIER; Takeda
Consulting or Advisory Role - Alderaan Biotechnology; Amgen; AstraZeneca; Avacta Life Sciences; BeiGene; BioNTech SE; Celanese; Domain Therapeutics; Ellipses Pharma; Genmab; Immunicom; Mariana Oncology; Nanobiotix; NextCure; Oncovita; Pierre Fabre; Seagen; Takeda; Tatum Bioscience; Tollys; UltraHuman8
Research Funding - Abbvie; Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen; Amgen (Inst); arGEN-X BVBA (Inst); Arno Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AVEO (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); BB Biotech Ventures (Inst); BBB Technologies (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAlliance Pharma (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics; Boston Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); CellCentric (Inst); Centessa Pharmaceuticals; Cephalon (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Cullinan Oncology (Inst); CureVac (Inst); Cytovation; Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eisai (Inst); Eisai/H3 Biomedicine; Exelixis (Inst); Faron Pharmaceuticals (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Glenmark (Inst); H3 Biomedicine (Inst); ImCheck therapeutics; Immunocore; Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Merus (Inst); Millennium (Inst); Molecular Partners; Molecular Partners (Inst); MSD; Nanobiotix (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Novartis (Inst); Octimet (Inst); Oncoethix (Inst); OncoMed (Inst); Oncopeptides (Inst); Onyx (Inst); Orion (Inst); Oryzon Genomics (Inst); OSE Immunotherapeutics; Ose Pharma (Inst); Pfizer (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); Pierre Fabre; Pierre Fabre (Inst); Pierre Fabre (Inst); Plexxikon (Inst); Relay Therapeutics (Inst); Replimune; RigonTEC (Inst); Roche (Inst); Roche (Inst); Roche/Genentech; Sanofi; Sanofi (Inst); Sanofi/Aventis (Inst); Seagen; Seagen (Inst); SERVIER (Inst); Sierra Oncology (Inst); Sotio; Sotio (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tioma Therapeutics (Inst); Transgene; Transgene (Inst); Turning Point Therapeutics (Inst); Veracyte (Inst); Wyeth (Inst); Xencor (Inst); Y's Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - T-cell immunogens derived from anti-viral proteins and methods of using same WO2010039223A2
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; MSD; OSE Immunotherapeutics; Roche; Sotio
Other Relationship - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); NH TherAguix (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; GT Aperion; Guardant Health; Harbinger Health; Incyte; Jazz Pharmaceuticals; LegoChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; OnCusp Therapeutics; Protai; Ribometrix; Seagen; Tempus; Theratechnologies; Zentalis; Zymeworks
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Cara Haymaker
Stock and Other Ownership Interests - Briacell
Consulting or Advisory Role - Regeneron
Research Funding - Avenge Bio (Inst); BTG (Inst); Dragonfly Therapeutics (Inst); Iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Obsidian Therapeutics (Inst); Sanofi (Inst); Yingli Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent Appl No. 62/977, 672 (Inst)
 
Ecaterina Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics; Fate Therapeutics; Mersana; PMV Pharma; Summit Therapeutics
Speakers' Bureau - PMV Pharma
Research Funding - A2A Pharmaceuticals (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Dragonfly Therapeutics (Inst); Fate Therapeutics (Inst); Genentech (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); Mersana (Inst); ModeX Therapeutics (Inst); Pfizer (Inst); PMV Pharma (Inst); Poseida (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Sotio (Inst); Triumvira Immunologics, Inc (Inst); Volastra Therapeutics (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Rain Oncology; Triumvira Immunologics, Inc